---
title: "PRLD.US (PRLD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRLD.US/news.md"
symbol: "PRLD.US"
name: "PRLD.US"
parent: "https://longbridge.com/en/quote/PRLD.US.md"
datetime: "2026-05-20T15:56:49.077Z"
locales:
  - [en](https://longbridge.com/en/quote/PRLD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRLD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRLD.US/news.md)
---

# PRLD.US (PRLD.US) — Related News

### [Prelude Therapeutics Launches Phase 1 Trial and Extends Runway](https://longbridge.com/en/news/286096254.md)
*2026-05-12T12:04:26.000Z*
> Prelude Therapeutics has launched a Phase 1 trial for its JAK2V617F inhibitor, PRT12396, after receiving U.S. regulatory

### [Prelude Therapeutics | 8-K: FY2026 Q1 Revenue: USD 4.58 M](https://longbridge.com/en/news/286089188.md)
*2026-05-12T11:24:58.000Z*
### [Prelude Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 4.58 M](https://longbridge.com/en/news/286088670.md)
*2026-05-12T11:21:17.000Z*
### [Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary](https://longbridge.com/en/news/286088885.md)
*2026-05-12T11:21:00.000Z*
> Prelude Therapeutics Inc reported Q1 2026 revenue of $4.58M, a significant increase from $0.0 in Q1 2025, driven by an u

### [Pre-market hot trades in US stocks: Prelude Therapeutics pre-market up 8.44%, driven by positive clinical data and dual benefits from new stock issuance boosting stock price surge](https://longbridge.com/en/news/283498720.md)
*2026-04-21T12:23:11.000Z*
> Prelude Therapeutics pre-market up 8.44%; Lobo Tech pre-market up 86.87%; Local Bounti pre-market up 52.13%; SciSparc pr

### [Prelude Therapeutics Prices Of $90 Mln Offering Of Shares And Pre-Funded Warrants](https://longbridge.com/en/news/283446003.md)
*2026-04-21T06:10:25.000Z*
> Prelude Therapeutics Incorporated (PRLD) has priced its offering of 18.02 million shares at $4.44 each, along with pre-f

### [](https://longbridge.com/en/news/283367271.md)
*2026-04-20T13:09:45.000Z*
> Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from